An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.

Targeting ZFP423 with antisense oligonucleotides enhances adipose thermogenesis, leading to greater fat loss and improved metabolic health in obese mice, with 40% more weight reduction.

• Why it matters: Current obesity treatments often cause lean mass loss and fat regain, limiting long-term effectiveness and metabolic benefits. Addressing these gaps could improve patient outcomes and sustain weight loss.
• What they did: Researchers developed ZFP423-targeting antisense oligonucleotides and tested them in lean and obese mice, combining them with GLP-1 receptor agonists to evaluate effects on thermogenesis, weight, and metabolism.
• The result: The combined therapy increased fat loss, preserved lean mass, and enhanced metabolic parameters, demonstrating ZFP423 as a promising RNA target for safer, more effective obesity treatments.